このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Lifecore Biomedical 将来の成長

Future 基準チェック /46

Lifecore Biomedicalは、138.1%と15.1%でそれぞれ年率138.1%で利益と収益が成長すると予測される一方、EPSはgrowで138.3%年率。

主要情報

138.1%

収益成長率

138.3%

EPS成長率

Life Sciences 収益成長	17.0%
収益成長率	15.1%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	22 Apr 2024

今後の成長に関する最新情報

Analysts Have Been Trimming Their Landec Corporation (NASDAQ:LNDC) Price Target After Its Latest Report

Apr 08

Recent updates

White Falcon Capital - Lifecore Biomedical: Potential For Rapid Growth In Earnings And FCF Surge

Apr 20

Analysts Have Been Trimming Their Landec Corporation (NASDAQ:LNDC) Price Target After Its Latest Report

Apr 08

Landec (NASDAQ:LNDC) Has A Somewhat Strained Balance Sheet

Mar 21

Here's What's Concerning About Landec's (NASDAQ:LNDC) Returns On Capital

Nov 30

Optimistic About Landec's Strategic Initiatives And Sodium Hyaluronate Products

Nov 05

Landec Still In Play As An Activist Investment

Aug 20

Is Landec (NASDAQ:LNDC) Using Too Much Debt?

May 25

Is Landec (NASDAQ:LNDC) Using Too Much Debt?

Feb 24

業績と収益の成長予測

NasdaqGS:LFCR - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
5/31/2026	164	N/A	N/A	N/A	1
5/31/2025	145	19	15	N/A	2
5/31/2024	126	7	2	N/A	2
5/28/2023	103	-64	-39	-17	N/A
2/26/2023	173	-87	-41	-20	N/A
11/27/2022	183	-78	-46	-25	N/A
8/28/2022	188	-67	-50	-27	N/A
5/29/2022	111	-15	-53	-23	N/A
2/27/2022	135	-12	-49	-18	N/A
11/28/2021	142	-7	-37	-8	N/A
8/29/2021	78	-6	-28	-1	N/A
5/30/2021	101	-23	-9	16	N/A
2/28/2021	283	-24	-18	-2	N/A
11/29/2020	391	-34	-2	16	N/A
8/30/2020	587	-44	-16	5	N/A
5/31/2020	160	-22	-44	-17	N/A
2/23/2020	587	-23	-39	-6	N/A
11/24/2019	590	-10	-46	-4	N/A
8/25/2019	572	-3	-32	8	N/A
5/26/2019	558	2	-29	16	N/A
2/24/2019	546	8	-29	17	N/A
11/25/2018	535	23	-24	18	N/A
8/26/2018	533	24	-24	19	N/A
5/27/2018	524	26	-14	20	N/A
2/25/2018	448	21	-7	27	N/A
11/26/2017	440	8	3	31	N/A
8/27/2017	453	9	0	27	N/A
5/28/2017	470	10	7	30	N/A
2/26/2017	540	13	N/A	39	N/A
11/27/2016	534	-12	N/A	25	N/A
8/28/2016	538	-11	N/A	30	N/A
5/29/2016	477	-12	N/A	21	N/A
2/28/2016	540	-12	N/A	19	N/A
11/29/2015	549	13	N/A	25	N/A
8/30/2015	541	14	N/A	20	N/A
5/31/2015	539	14	N/A	27	N/A
3/1/2015	526	14	N/A	21	N/A
11/30/2014	514	17	N/A	20	N/A
8/31/2014	501	17	N/A	20	N/A
5/25/2014	477	19	N/A	21	N/A
2/23/2014	463	19	N/A	22	N/A
11/24/2013	454	18	N/A	23	N/A
8/25/2013	449	23	N/A	21	N/A

アナリストによる今後の成長予測

収入対貯蓄率: LFCRは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.4% ) よりも高い成長率であると考えられます。

収益対市場: LFCR今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: LFCR今後 3 年以内に収益を上げることが予想されます。

収益対市場: LFCRの収益 ( 15.1% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: LFCRの収益 ( 15.1% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: LFCRの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Lifecore Biomedical 将来の成長

Future 基準チェック /46

主要情報

今後の成長に関する最新情報

Lifecore Biomedical, Inc. Provides Revenue Guidance for Full Year Fiscal 2024

Price target decreased by 86% to US$2.00

Price target decreased to US$13.75

Landec Corporation Reiterates Revenue Guidance for the Full Year Fiscal 2023

Landec Corporation Provides Revenue Guidance for the Full Year Fiscal 2023

Analysts Have Been Trimming Their Landec Corporation (NASDAQ:LNDC) Price Target After Its Latest Report

Recent updates

Lifecore Biomedical Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Requirements for Continued Listing Under Nasdaq Listing Rule 5620(a)

Lifecore Biomedical, Inc., Annual General Meeting, Aug 15, 2024

White Falcon Capital - Lifecore Biomedical: Potential For Rapid Growth In Earnings And FCF Surge

Lifecore Biomedical, Inc. announced delayed 10-Q filing

Lifecore Biomedical, Inc. Provides Revenue Guidance for Full Year Fiscal 2024

Lifecore Biomedical, Inc. Announces Chief Executive Officer Changes, Effective May 20, 2024

Lifecore Biomedical Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal

Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Quarterly Report

Lifecore Biomedical, Inc. announced delayed 10-Q filing

Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Annual Report

Lifecore Biomedical, Inc. announced delayed 10-Q filing

Lifecore Biomedical Receives Notice from Nasdaq Regarding Delayed Quarterly Report

Would Lifecore Biomedical (NASDAQ:LFCR) Be Better Off With Less Debt?

Lifecore Biomedical, Inc.(NasdaqGS:LFCR) dropped from Russell 2000 Dynamic Index

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 86% to US$2.00

High number of new directors

Lifecore Biomedical Receives A Notification Letter from Nasdaq Due to Delay in Filing Its Quarterly Report on Form 10-Q for the Period Ended November 27, 2022

Lifecore Biomedical, Inc. announced that it has received $38.75 million in funding from Legion Partners Asset Management, LLC, 22NW, LP, 325 Capital, LLC, Cove Street Partners, Wynnefield Capital, Inc.

Lifecore Biomedical, Inc. announced delayed 10-Q filing

Lifecore Biomedical, Inc. announced that it has received $5.003136 million in funding

Price target decreased to US$13.75

Landec Corporation Reiterates Revenue Guidance for the Full Year Fiscal 2023

Landec Non-GAAP EPS of -$0.32, revenue of $43.35M

Landec Corporation to Report Q1, 2023 Results on Oct 06, 2022

Landec Corporation, Annual General Meeting, Nov 01, 2022

Landec Corp. Receives Notice from Nasdaq Regarding Delayed Annual Report

Landec receives Nasdaq's notification on delayed annual report filing

Landec Corporation announced delayed annual 10-K filing

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Landec Corporation Provides Revenue Guidance for the Full Year Fiscal 2023

VP & President of Lifecore exercised options to buy US$76k worth of stock.

Laughing Water Capital - Landec Corp. : A High Quality CDMO

Landec Corporation(NasdaqGS:LNDC) dropped from Russell 2000 Value-Defensive Index

Landec (NASDAQ:LNDC) Takes On Some Risk With Its Use Of Debt

Independent Director exercised options to buy US$70k worth of stock.

CEO, President & Director exercised options to buy US$269k worth of stock.

High number of new directors

Analysts Have Been Trimming Their Landec Corporation (NASDAQ:LNDC) Price Target After Its Latest Report

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Landec Corporation Reiterates Consolidated Earnings Guidance for the Fiscal Year 2022

Landec (NASDAQ:LNDC) Has A Somewhat Strained Balance Sheet

High number of new directors

Independent Director recently bought US$104k worth of stock

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Landec Corporation Provides Consolidated Revenue Guidance for Full Year Fiscal 2022

Price target increased to US$15.00

Consensus revenue estimates fall by 66%

Here's What's Concerning About Landec's (NASDAQ:LNDC) Returns On Capital

Optimistic About Landec's Strategic Initiatives And Sodium Hyaluronate Products

Landec Corporation Provides Earnings Guidance for the First Half, Second Half and Full Year of Fiscal 2022

First quarter 2022 earnings released: US$322 loss per share (vs US$0.38 loss in 1Q 2021)

Landec Still In Play As An Activist Investment

Independent Director Patrick Walsh has left the company

Consensus forecasts updated

Price target increased to US$14.40

Full year 2021 earnings released: US$1.12 loss per share (vs US$1.31 loss in FY 2020)

President of Lifecore exercised options to buy US$61k worth of stock.

Independent Director exercised options to buy US$106k worth of stock.

Is Landec (NASDAQ:LNDC) Using Too Much Debt?

Price target decreased to US$13.25

President of Lifecore recently bought US$106k worth of stock

Consensus EPS estimates fall to -US$1.03

Price target decreased to US$13.25

Third quarter 2021 earnings released: US$0.19 loss per share (vs US$0.40 loss in 3Q 2020)

Landec Corporation Provides Revenue Guidance for the Full Fiscal Year 2021

Senior VP of Human Resources & Chief People Officer has left the company

New 90-day high: US$12.22

Landec Corporation Announces Resignation of Dawn Kimball as Senior Vice President and Chief People Officer, Effective March 12, 2021